Shingrix vaccine under the microscope: can it shield patients on Immune-Weakening drugs?
NCT ID NCT07534007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the Shingrix vaccine (for shingles) works in people with psoriasis or myelofibrosis who are taking drugs that weaken their immune system. Researchers will compare their immune response to that of similar patients not on these drugs. The goal is to understand if the vaccine still provides strong protection in these vulnerable groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
RECRUITINGPavia, Lombarda, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill shrink the spleen in myelofibrosis?
- Can a daily pill shrink the spleen in myelofibrosis?
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?